Details for New Drug Application (NDA): 208700
✉ Email this page to a colleague
NDA 208700 describes LUTATHERA, which is a drug marketed by Aaa Usa Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the LUTATHERA profile page.
The generic ingredient in LUTATHERA is lutetium lu 177 dotatate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lutetium lu 177 dotatate profile page.
The generic ingredient in LUTATHERA is lutetium lu 177 dotatate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lutetium lu 177 dotatate profile page.
Summary for 208700
| Tradename: | LUTATHERA |
| Applicant: | Aaa Usa Inc |
| Ingredient: | lutetium lu 177 dotatate |
| Patents: | 3 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208700
Generic Entry Date for 208700*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 208700
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUTATHERA | lutetium lu 177 dotatate | SOLUTION;INTRAVENOUS | 208700 | NDA | Advanced Accelerator Applications USA, Inc | 69488-003 | 69488-003-01 | 1 VIAL in 1 PACKAGE (69488-003-01) / 20.5 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 10mCi/ML | ||||
| Approval Date: | Jan 26, 2018 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Apr 23, 2027 | ||||||||
| Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
| Regulatory Exclusivity Expiration: | Jul 26, 2025 | ||||||||
| Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
| Regulatory Exclusivity Expiration: | Oct 23, 2027 | ||||||||
| Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Complete Access Available with Subscription
